Indazole derivatives as antagonists of the muscarinic acetylcholine receptor m4

A compound of formula (I):

• or a pharmaceutically acceptable salt thereof, wherein:
• G1 is
• R is hydrogen, C1-4alkyl, C3-4cycloalkyl, or —C1-3alkylene-C3-4cycloalkyl;
• R1a is hydrogen, C1-4alkyl, C1-4fluoroalkyl, —OC1-4alkyl, —OC1-4fluoroalkyl, —OC3-6cycloalkyl, —OCH2C3-6cycloalkyl, —SO2C1-4alkyl, —SO2C3-6cycloalkyl, phenyl, or C3-6cycloalkyl, wherein the phenyl and each C3-6cycloalkyl are optionally substituted with 1-4 substituents independently selected from the group consisting of halogen, cyano, C1-4alkyl, C1-4haloalkyl, —OC1-4alkyl, and —OC1-4haloalkyl;
• R1b is hydrogen, halogen, cyano, C1-4alkyl, C1-4fluoroalkyl, or C3-6cycloalkyl;
• or alternatively, R1a and R1b, together with the atoms to which they attach, form a five- or six-membered unsaturated or partially unsaturated carbocyclic or heterocyclic ring, the carbocyclic or heterocyclic ring being unsubstituted or substituted with 1-4 substituents independently selected from the group consisting of halogen, cyano, C1-4alkyl, C1-4fluoroalkyl, C2-4alkenyl, C3-6cycloalkyl, and —C1-3alkylene-C3-4cycloalkyl;
• R2a is C1-4alkyl, C1-4fluoroalkyl, C3-4cycloalkyl, or —C1-3alkylene-C3-4cycloalkyl;
• R2b is C1-4alkyl, C1-4fluoroalkyl, C3-4cycloalkyl, or —C1-3alkylene-C3-4cycloalkyl;
• R3 is -L1-G2, G2, -L2-G2, -L2-L1-G2, —C2-6alkylene-R3a, C3-7alkyl, or C3-7haloalkyl;
• L1 is C1-5alkylene or C1-5fluoroalkylene;
• L2 is 1,1-cyclopropylene;
• G2 is a 4- to 12-membered heterocyclyl, a 6- to 12-membered aryl, a 5- to 12-membered heteroaryl, or a C3-12carbocyclyl optionally fused to a 6-membered arene, wherein G2 is optionally substituted with 1-5 substituents independently selected from the group consisting of halogen, cyano, oxo, C1-4alkyl, C1-4haloalkyl, —OR13, —N(R13)2, —C1-3alkylene-OR13, and —C1-3alkylene-N(R13)2;
• R3a is —OR14 or —N(R14)2;
• R13, at each occurrence, is independently hydrogen, C1-4alkyl, C1-4haloalkyl, C3-4cycloalkyl, or —C1-3alkylene-C3-4cycloalkyl, wherein alternatively two R13, together with a nitrogen to which the two R13 attach form a 4- to 6-membered heterocyclic ring optionally substituted with 1-4 substituents independently selected from the group consisting of halogen and C1-4alkyl;
• R14, at each occurrence, is independently hydrogen, C1-4alkyl, C1-4haloalkyl, G3, or —C1-3alkylene-G3, wherein alternatively two R14, together with a nitrogen to which the two R14 attach form a 4- to 6-membered heterocyclic ring optionally substituted with 1-4 substituents independently selected from the group consisting of halogen and C1-4alkyl;
• G3 is phenyl, a monocyclic 5- to 6-membered heteroaryl, a monocyclic 4- to 8-membered heterocyclyl, or a monocyclic C3-8cycloalkyl, wherein G3 is optionally substituted with 1-5 substituents independently selected from the group consisting of halogen, cyano, C1-4alkyl, C1-4haloalkyl, oxo, —OR15, and —N(R15)2;
• and
• R15, at each occurrence, is independently hydrogen, C1-4alkyl, C1-4haloalkyl, C3-4cycloalkyl, or —C1-3alkylene-C3-4cycloalkyl, wherein alternatively two Ris, together with a nitrogen to which the two R15 attach form a 4- to 6-membered heterocyclic ring optionally substituted with 1-4 substituents independently selected from the group consisting of halogen and C1-4alkyl;
• provided the compound is not:
• 7-(2,4-dimethyl-2H-indazol-5-yl)-N-((3aR,5s,6aS)-2-((tetrahydro-2H-pyran-4-yl)methyl)octahydrocyclopenta[c]pyrrol-5-yl)thieno[2,3-d]pyridazin-4-amine;
• (3aR,5s,6aS)—N-(6-(2,4-dimethyl-2H-indazol-5-yl)-4-methoxypyridazin-3-yl)-2-((tetrahydro-2H-pyran-4-yl)methyl)octahydrocyclopenta[c]pyrrol-5-amine;
• (3aR,5s,6aS)—N-(6-(2,4-dimethyl-2H-indazol-5-yl)-5-methylpyridazin-3-yl)-2-((tetrahydro-2H-pyran-4-yl)methyl)octahydrocyclopenta[c]pyrrol-5-amine;
• (3aR,5s,6aS)—N-(6-(2,4-dimethyl-2H-indazol-5-yl)-4-methylpyridazin-3-yl)-2-((tetrahydro-2H-pyran-4-yl)methyl-d2)octahydrocyclopenta[c]pyrrol-5-amine;
• (3aR,5s,6aS)—N-(4-(difluoromethyl)-6-(2,4-dimethyl-2H-indazol-5-yl)pyridazin-3-yl)-2-((tetrahydro-2H-pyran-4-yl)methyl)octahydrocyclopenta[c]pyrrol-5-amine;
• (3aR,5s,6aS)—N-(6-(2,4-dimethyl-2H-indazol-5-yl)-4-(trifluoromethyl)pyridazin-3-yl)-2-((tetrahydro-2H-pyran-4-yl)methyl)octahydrocyclopenta[c]pyrrol-5-amine;
• or
• (3aR,5s,6aS)—N-(6-(2,4-dimethyl-2H-indazol-5-yl)-5-(trifluoromethyl)pyridazin-3-yl)-N-(methyl-d3)-2-((tetrahydro-2H-pyran-4-yl)methyl)octahydrocyclopenta[c]pyrrol-5-amine;
• or a pharmaceutically acceptable salt thereof.